Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aceclofenac. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 7/20 | 0.78 |
| ▸ | TTR | P02766 | 3/20 | 0.95 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.95 |
| ▸ | USP2 | O75604 | 1/20 | 0.95 |
| ▸ | LMNA | P02545 | 1/20 | 0.95 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.95 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.95 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.95 |
| ▸ | CXCL8 | P10145 | 3/20 | 0.78 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.78 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.78 |
| ▸ | UGT1A9 | O60656 | 1/20 | 0.78 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.78 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.78 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.78 |
| ▸ | ALB | P02768 | 1/20 | 0.78 |
| ▸ | UGT1A6 | P19224 | 1/20 | 0.78 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.78 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.78 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aceclofenac SCHEMBL29364020 | 0.97 | TTR (1.00) | TTRCYP2C9USP2LMNATBXA2R | |
| Aceclofenac SCHEMBL25734 | 0.97 | TTR (1.00) | TTRCYP2C9USP2LMNATBXA2R | |
| Aceclofenac SCHEMBL27918955 | 0.96 | TTR (0.97) | TTRCYP2C9USP2LMNATBXA2R | |
| Aceclofenac SCHEMBL28443210 | 0.96 | TTR (0.97) | TTRCYP2C9USP2LMNATBXA2R | |
| Aceclofenac SCHEMBL2905138 | 0.96 | TTR (0.97) | TTRCYP2C9USP2LMNATBXA2R | |
| Aceclofenac SCHEMBL16697727 | 0.96 | TTR (0.97) | TTRCYP2C9USP2LMNATBXA2R | |
| Aceclofenac SCHEMBL28873275 | 0.95 | TTR (0.95) | TTRCYP2C9USP2LMNATBXA2R | |
| Aceclofenac SCHEMBL15268397 | 0.95 | TTR (0.95) | TTRCYP2C9USP2LMNATBXA2R | |
| Aceclofenac SCHEMBL29775490 | 0.91 | TTR (0.86) | TTRCYP2C9USP2LMNATBXA2R | |
| Diclofenac SCHEMBL29354260 | 0.88 | PTGS2 (1.00) | TTRCYP2C9USP2LMNATBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030004128-A1 | Formulatios of adenosine a1 agonists | BOUNTRA CHARANJIT (GB) | 2003-01-02 | — | — | US | claimed |
| EP-1239879-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2002-09-18 | — | — | EP | claimed |
| WO-2001045683-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2001-06-28 | — | — | WO | claimed |
| US-7390817-B2 | Combinations of a vanilloid antagonist and an NSAID for the treatment of pain | GLAXO GROUP LIMITED (GB) | 2008-06-24 | — | — | US | disclosed |
| US-20060093687-A1 | Combinations of a vanilloid antagonist and an nsaid for the treatment of pain | BOUNTRA CHARANJIT | 2006-05-04 | — | — | US | disclosed |
| EP-1572237-A1 | COMBINATIONS OF VANILLOID ANTAGONIST AND NSAID FOR THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004056394-A1 | COMBINATIONS OF A VANILLOID ANTAGONIST AND AN NSAID FOR THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2004-07-08 | — | — | WO | disclosed |
| US-20030004128-A1 | Formulatios of adenosine a1 agonists | BOUNTRA CHARANJIT (GB) | 2003-01-02 | — | — | US | disclosed |
| EP-1239879-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001045683-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2001-06-28 | — | — | WO | disclosed |
| WO-1997013519-A1 | ESTERS OF CYCLOOXYGENASE INHIBITORS AND TERPENE DERIVATIVES AS PHARMACEUTICAL PRODUCTS | RUSSINSKY LIMITED (IE) | 1997-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060093687-A1 | Combinations of a vanilloid antagonist and an nsaid for the treatment of pain | TRPV1, TRPV2, TRPV3 | PTGS2 129/4885TTR 1914/4885CYP2C9 809/4885 |
| US-20030004128-A1 | Formulatios of adenosine a1 agonists | ADORA1, ADORA2A, ADORA2B | PTGS2 25/4885TTR 2681/4885CYP2C9 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.